Molecular Bio-Imaging Probe for Non-Invasive Differentiation Between Human Leiomyoma Versus Leiomyosarcoma
Leiomyosarcoma is the most frequent subtype of the deadly uterine sarcoma and shares many common clinical grounds with leiomyoma, which is in turn the most common solid benign uterine neoplasm. With the recent progress in minimally invasive techniques for managing leiomyomas, accurate preoperative diagnosis of uterine masses has become the most important selection criterion for the safest therapeutic option. Therefore, different imaging modalities would be playing a key role in management of uterine masses. Testing for a sarcoma-specific promoter that expresses its downstream reporter gene only in leiomyosarcoma and not in leiomyoma or healthy uterine tissue. Adenoviral vectors were utilized both in vitro and in vivo to test the specificity of the promoters. Quantitative studies of downstream gene expression of these promoters was carried out both in vitro and in vivo. Our data indicated that human leiomyosarcoma cells highly expressed the reporter gene downstream to survivin promoter (Ad-SUR-LUC) when compared with benign leiomyoma or normal cells (p value of 0.05). Our study suggested that survivin is the unique promoter capable of distinguishing between the deadly sarcoma and the benign counterparts.
KeywordsMolecular imaging probe Leiomyosarcoma Sarcoma-specific promoter
Dr. Al-Hendy conceived the idea, developed the theory, designed the study, edited and revised the manuscript; Dr. Shahinaz Shalaby and Dr. Mostafa Khater collected, analyzed the data, wrote the manuscript. Ms. Archana Laknaur prepared for the experiments. Dr. Arbab facilitated the spectral imaging studies, revised the protocols, and edited the manuscript. All authors provided critical feedback and helped shape the research, analysis, and manuscript.
This study was funded by the National Institute of Health (R01 ES 028615–01, R01HD 087417, R01 HD 094378, R01 HD 094380).
Compliance with Ethical Standards
Conflict of Interest
Dr. Ayman Al-Hendy is consulting Abbvie, Bayer, Allergan, MD Stem Cells for research support. Dr. Ali Arbab declares that he has no conflict of interest. Ms. Archana Laknaur declares that she has no conflict of interest. Dr.Mostafa Khater declares that he has no conflict of interest. Dr. Shahinaz Shalaby declares that she has no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed, and IACUC approval of Augusta University was taken. This article does not contain any studies with human participants performed by any of the authors.
- 10.White M. Uterine smooth muscle tumors of uncertain malignant potential (stump): review of pathophysiology, classification, diagnosis, treatment, and surveillance. J Health Commun. 2017;2:4. https://doi.org/10.4172/2472-1654.100080.
- 28.Al-Hendy, A., Lee, E. J., Wang, H. Q., & Copland, J. A. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. American journal of obstetrics and gynecology, (2004);191(5):1621-1631.Google Scholar
- 29.Salama, S. A., Kamel, M., Christman, G., Wang, H. Q., Fouad, H. M., & Al-Hendy, A. Gene therapy of uterine leiomyoma: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells in vitro and in a nude mouse model. Gynecologic and obstetric investigation, (2007);63(2):61-70.Google Scholar
- 31.Kotz S, Balakrishnan N, Read CB, Vidakovic B. Encyclopedia of statistical sciences. 2nd ed. Hoboken: Wiley-Interscience; 2006.Google Scholar
- 32.Nair, S., Curiel, D. T., Rajaratnam, V., Thota, C., & Al-Hendy, A. Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas. Human Reproduction, (2013);28(9):2398-2406.Google Scholar